Aggressive posttransplant lymphoproliferative disease in a renal transplant patient treated with alemtuzumab

American Journal of Therapeutics

Volumn 17, Issue 6, 2010, Pages

  Muzaffar, Mahvish ^a   Taj, Asma ^a   Ratnam, Shobha ^a  

^a UNIVERSITY OF TOLEDO MEDICAL CENTER   (United States)

Author keywords

alemtuzumab; colonic perforation; EBV; PTLD; renal transplant; rituximab

Indexed keywords

ALEMTUZUMAB; CD19 ANTIGEN; CD20 ANTIGEN; CD45 ANTIGEN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RITUXIMAB; TACROLIMUS;

ABDOMINAL PAIN; ACUTE KIDNEY FAILURE; ADULT; ARTICLE; CADAVER KIDNEY; CANCER DIAGNOSIS; CANCER STAGING; CANCER SURGERY; CASE REPORT; CHRONIC KIDNEY DISEASE; COLONOSCOPY; CONSERVATIVE TREATMENT; EPSTEIN BARR VIRUS; EPSTEIN BARR VIRUS INFECTION; ESOPHAGOGASTRODUODENOSCOPY; FLOW CYTOMETRY; GASTROINTESTINAL HEMORRHAGE; GLOMERULONEPHRITIS; HEMICOLECTOMY; HISTOPATHOLOGY; HUMAN; ILEOSTOMY; IMMUNOSUPPRESSIVE TREATMENT; INTESTINE ANASTOMOSIS; INTESTINE NECROSIS; INTESTINE OBSTRUCTION; KIDNEY TRANSPLANTATION; LAPAROTOMY; LARGE CELL LYMPHOMA; LARGE INTESTINE PERFORATION; MALE; MITOSIS INDEX; PALLIATIVE THERAPY; POSITRON EMISSION TOMOGRAPHY; POSTOPERATIVE COMPLICATION; POSTOPERATIVE HEMORRHAGE; PRIORITY JOURNAL; RECURRENT DISEASE; SMALL INTESTINE PERFORATION; SMALL INTESTINE RESECTION;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIBODIES, NEOPLASM; EPSTEIN-BARR VIRUS INFECTIONS; FATAL OUTCOME; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; LYMPHOPROLIFERATIVE DISORDERS; MALE; MIDDLE AGED;

EID: 78649510429     PISSN: 10752765     EISSN: None     Source Type: Journal    
DOI: 10.1097/MJT.0b013e3181c08042     Document Type: Article

References (20)

1. Penn I. Occurrence of cancers in immunosuppressed organ transplant recipients. Clin Transpl. 1998;12:147-158.
2. Ruiz P, Garcia M, Nicolas M, et al. Lymphoplasmacytic hyperplasia (possibly pre-PTLD) has varied expression and appearance in intestinal transplant recipients re-ceiving Campath immunosuppression. Transplant Proc. 2004;2:386-387.
3. Opelz G, Döhler B. Lymphomas after solid organ transplantation: a collaborative transplant study report. Am J Transplant. 2003;4:222-230.
4. Shapiro R, Nalesnik M, Mc Cauley J, et al. Posttransplant lymphoproliferative disorders in adult and pediatric renal transplant patients receiving tacrolimus-based immuno-suppression. Transplantation. 1999;68:1851-1854.
5. Cockfield SM, Preiksaitis JK, Jewell LD, et al. Post-transplant lymphoproliferative disorder in renal allograft recipients. Clinical experience and risk factor analysis in a single center. Transplantation. 1993;56:88-96.
6. Charpentier B, Hiesse C, Marchand S, et al. Induction therapies with polyclonal antithymocyte globulins or monoclonal antibodies. Transplant Proc. 2000;32:367.
7. Mc Donald RA, Smith JM, Ho M, et al. Incidence of PTLD in pediatric renal transplant recipients receiving basilix-imab, calcineurin inhibitor, sirolimus and steroids. Am J Transplant. 2008;8:984-989.
8. Ciancio G, Siquijor AP, Burke GW, et al. Post-transplant lymphoproliferative disease in kidney transplant patients in the new immunosuppressive era. Clin Transplant. 1997; 11:243-249.
9. Ciancio G, Burke GW, Gaynor JJ, et al. The use of Campath-1H as induction therapy in renal trans-plantation: preliminary results. Transplantation. 2004;78: 426-429.
10. Kirk AD, Cherikh WS, Ring M, et al. Dissociation of depletional induction and posttransplant lymphoproli-ferative disease in kidney recipients treated with alemtu-zumab. Am J Transplant. 2007;7:2619-2625.
11. Snyder MJ, Stenzel TT, Gong JZ. Posttransplant lympho-proliferative disorder following nonmyeloablative allo-geneic stem cell transplantation. Am J Surg Pathol. 2004;28: 794-800.
12. Hanneke C, Kluin-Nelemans JLC, Boers JE, et al. EBV-positive immunodeficiency lymphoma after alemtuzu-mab-CHOP therapy for peripheral T-cell lymphoma. Blood. 2008;112:1039-1041.
13. Roch N, Salameire D, Gressin R, et al. Fatal adenoviral and enteroviral infections and an Epstein-Barr virus positive large B-cell lymphoma after alemtuzumab treatment in a patient with refractory Sézary syndrome. Scand J Infect Dis. 2008;40:343-346.
14. Nalesnik MA. Clinicopathologic features of posttrans-plant lymphoproliferative disorders. Ann Transplant. 1997;2:33-40.
15. Starzl TE, Penn I, Halgrimson CG. Immunosup-pression and malignant neoplasms. N Engl J Med. 1970; 283:934.
16. Benkerrou M, Durandy A, Fisher A. Therapy for trans-plant-related lymphoproliferative diseases. Hematol Oncol Clin North Am. 1993;7:467.
17. Faller DV, Mentzer SJ, Perrine SP. Induction of the Epstein-Barr virus thymidine kinase gene with concom-itant nucleoside antivirals as a therapeutic strategy for Epstein-Barr virus-associated malignancies. Curr Opin Oncol. 2001;13:360-367.
18. Trappe R, Riess H, Anagnostopoulos I, et al. Efficiency of antiviral therapy plus IVIG in a case of primary EBV infection associated PTLD refractory to rituximab, chemotherapy, and antiviral therapy alone. Ann Hematol. 2009;88:167-172.
19. Gross TG. Treatment for Epstein-Barr virus-associated PTLD. Herpes. 2009;15:64-67.
20. Rooney CM, Smith CA, Ng CY. Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recip-ients. Blood. 1998;92:1549.